Global Mitomycin C Market Projected huge Growth by 2023
Qurate Research announces the addition of new study based research report on “Global Mitomycin C Consumption Market” to their suite of offerings.
(EMAILWIRE.COM, October 18, 2018 ) Mitomycin C market, Mitomycin C is an antibiotic which acts as a double-stranded DNA alkylating agent. It covalently crosslinks DNA, inhibiting DNA synthesis and cell proliferation It acts by way of reductive activation either through low pH or NAD(P)Quinone oxidoreductase (DT-diaphorase) or NADH cytochrome c reductase (Mao et al.; Cummings et al.). In the last several years, Global market of Mitomycin C was experienced an upward trend rapidly, with an average growth rate of 4.76%. In 2016, Global Revenue of Mitomycin C is nearly 119.83 M USD; the actual production is about 17370 K Unit. The global average price of Mitomycin C is in the increasing trend, from 6.30 USD/Unit in 2012 to 6.90 USD/Unit in 2016. With the situation of global economy, prices will be in increasing trend in the following five years. The classification of Mitomycin C includes 2 Mg, 10 Mg, 40 Mg, and others. The proportion of 2 Mg in 2016 is about 41.5%, and the proportion is in decreasing trend from 2012 to 2016. Mitomycin C is widely used in Cancer Treatment, Ophthalmic Use, and another field. The most proportion of Mitomycin C is Cancer Treatment, and the proportion in 2016 is 69%. The trend of Cancer Treatment is decreasing.
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-LPI-HnM-5424
Japan is the largest supplier of Mitomycin C, with a production market share nearly 26.5% in 2016. India is the second largest supplier of Mitomycin C Media, enjoying production market share nearly 25% in 2016. North America is the largest consumption place, with a consumption market share nearly 36% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 32.6%. Market competition is not intense. Kyowa-kirin, Intas Pharmaceuticals, Teva, Bristol-Myers Squibb, Aspen, Speciality European Pharma, etc. are the leaders of the industry. Over the next five years, expert projects that Mitomycin C will register a -2.3% CAGR in terms of revenue, reach US$ 100 million by 2023, from US$ 120 million in 2017.
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Kyowa-kirin
Intas Pharmaceuticals
Teva
Bristol-Myers Squibb
Aspen
Speciality European Pharma
Alkem Laboratories
Varifarma
APOGEPHA
To calculate the market size, expert considers value and volume generated from the sales of the following segments:
Segmentation by product type:
2 Mg
10 Mg
40 Mg
Other
Segmentation by application:
Cancer Treatment
Ophthalmic Use
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
For Enquiry, Visit@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-LPI-HnM-5424
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives:
To study and analyze the global Mitomycin C consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Mitomycin C market by identifying its various subsegments.
Focuses on the key global Mitomycin C manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Mitomycin C with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Mitomycin C submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Direct Purchase: https://www.qurateresearch.com/report/buy/HnM/QBI-LPI-HnM-5424/
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-LPI-HnM-5424
Japan is the largest supplier of Mitomycin C, with a production market share nearly 26.5% in 2016. India is the second largest supplier of Mitomycin C Media, enjoying production market share nearly 25% in 2016. North America is the largest consumption place, with a consumption market share nearly 36% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 32.6%. Market competition is not intense. Kyowa-kirin, Intas Pharmaceuticals, Teva, Bristol-Myers Squibb, Aspen, Speciality European Pharma, etc. are the leaders of the industry. Over the next five years, expert projects that Mitomycin C will register a -2.3% CAGR in terms of revenue, reach US$ 100 million by 2023, from US$ 120 million in 2017.
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Kyowa-kirin
Intas Pharmaceuticals
Teva
Bristol-Myers Squibb
Aspen
Speciality European Pharma
Alkem Laboratories
Varifarma
APOGEPHA
To calculate the market size, expert considers value and volume generated from the sales of the following segments:
Segmentation by product type:
2 Mg
10 Mg
40 Mg
Other
Segmentation by application:
Cancer Treatment
Ophthalmic Use
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
For Enquiry, Visit@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-LPI-HnM-5424
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives:
To study and analyze the global Mitomycin C consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Mitomycin C market by identifying its various subsegments.
Focuses on the key global Mitomycin C manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Mitomycin C with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Mitomycin C submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Direct Purchase: https://www.qurateresearch.com/report/buy/HnM/QBI-LPI-HnM-5424/
Contact Information:
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results